Assessment of a Dazel-Kit (Fluconazole 150 mg, Azithromycin 1 gm, Secnidazole 1 g Two Tablets) for Syndromic Management of Abnormal Vaginal Discharge in Women of Kazakhstan
International Journal of Research and Reports in Gynaecology,
Objective: Present study aimed to assess the effectiveness and safety of Dazel kit (fluconazole 150 mg, azithromycin 1 gm, secnidazole 1 g two tablets) among patients with vaginal infections.
Materials and Methods: In this observational study, 705 clinically diagnosed patients with abnormal vaginal discharge were enrolled in four different cities of Kazakhstan. Clinical features, treatment given, improvement in symptoms and adverse events were noted. Improvement in clinical features with Dazel kit was rated on a 4-point scale; 1=no effect; 2=somewhat effective; 3=effective; 4= highly effective.
Results: Abnormal vaginal discharge was the most common symptom (91.5%), followed by itching (88.2%) and lower abdominal pain (59.6%). For all patients, Dazel kit was recommended, whereas in 617 patients (87.5%), it was recommended for their partner(s) too. In 90 patients (12.8%) only Dazel kit was recommended alone whereas, in 615 patients (87.23%), vaginal treatment was recommended in addition to Dazel kit. In 99.2% patients with abnormal vaginal discharge and vaginal itching, treatment was effective or highly effective. For the control of dyspareunia, lower abdominal pain and burning sensation with urination, treatment was found to be effective or highly effective in 64.3%, 98.7% and 95.4% patients, respectively. No significant difference was observed in the “highly effective” and “effective” response for any of the symptoms between treatment only to the female patient and treatment to patient and her partner(s) [abnormal vaginal discharge (p= 0.755), vaginal itching (p= 0.512), dyspareunia (p= 0.791), lower abdominal pain (p= 0.964) or burning sensation (Pp= 0.804)].
Conclusion: Dazel kit was found to be effective in the treatment of vaginal symptoms in majority of the patients without significant adverse events.